CytoMed Therapeutics Limited (GDTC) Stock

About CytoMed Therapeutics Limited

CytoMed Therapeutics Limited is led by CEO Chee Kong Choo, employs 43 people, headquartered in SG, publicly traded since 2023.

CytoMed Therapeutics Limited (GDTC) stock trades at $0.92 with a market capitalization of $10.87M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.56, reflecting a net loss over the last twelve months, price-to-book of 2.81, price-to-sales of 20.92. Over the past 52 weeks the stock has ranged between $0.68 and $3.68, and currently trades 75.0% below its 52-week high.

On profitability, CytoMed Therapeutics Limited generates a return on equity (ROE) of -87.20% (negative, reflecting a net loss), return on capital employed of -98.10%, an operating margin of -10.75%, a net profit margin of -826.34%.

CytoMed Therapeutics Limited by the numbers, 2019–2025

Between 2019 and 2025 CytoMed Therapeutics Limited reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-4.0M.

The most recent net margin is -826.34%. On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-6.0M.

Borrowings fell from $1.0M to $0, cash from operations was $-4.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged -98.7% over five years, and was -57.1% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

CytoMed Therapeutics Limited (GDTC) — frequently asked questions